StockData

Septerna vs vTv Therapeutics

SEPN and VTVT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SEPN and VTVT compare

Septerna is the larger company, worth 27 times as much as vTv Therapeutics ($1.9B against $68.4M).

vTv Therapeutics grew revenue faster over the last twelve months (216600% versus 337% for Septerna).

vTv Therapeutics keeps more of each dollar of sales as profit, with a net margin of −12.9% compared with −61.3% at Septerna.

vTv Therapeutics scores higher on the StockData Score (11 against 8 for Septerna), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSEPNVTVT
Size and price
Market cap$1.9B$68.4M
Share price$40.02$17.29
Change, 1 year72.0%−43.9%
Change, 5 years–−67.7%
Beta (5Y)0.700.08
Employees13026
StockData Score
Total score811 (better)
Valuation score03 (better)
Growth score11
Performance score12 (better)
Health score6 (better)5
Dividend score00
Valuation
P/S19.4×1.9× (better)
P/B4.4×0.9× (better)
FCF yield−4.2%–
Fair value$15.08$44.97
Margin of safety−165%61.6% (better)
Growth
Revenue growth (TTM)337%216600% (better)
Profitability
Operating margin−76.2%−25.1% (better)
Net margin−61.3%−12.9% (better)
FCF margin−80.6%–
Return on equity−14.4%−11.7% (better)
Financial health
Debt / equity0.000.00
Current ratio4.8412.48 (better)
Altman Z-score5.91 (better)0.71
Piotroski F-score5 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions102%40.6%
Held by insiders27.9%26.3%
Insider net buying, 12 months−$80.9M–
Short interest, % of float10.0%5.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.